Kraj: Kanada
Język: angielski
Źródło: Health Canada
QUETIAPINE (QUETIAPINE FUMARATE)
TEVA CANADA LIMITED
N05AH04
QUETIAPINE
150MG
TABLET
QUETIAPINE (QUETIAPINE FUMARATE) 150MG
ORAL
100
Prescription
ATYPICAL ANTIPSYCHOTICS
Active ingredient group (AIG) number: 0131858004; AHFS:
CANCELLED POST MARKET
2021-07-30
_____________________________________________________________________________ _TEVA-QUETIAPINE Page 1 of 56 _ PRODUCT MONOGRAPH Pr TEVA-QUETIAPINE (Quetiapine as Quetiapine Fumarate) 25 mg, 100 mg, 150 mg, 200 mg and 300 mg Tablets Teva Standard Antipsychotic Agent Teva Canada Limited 30 Novopharm Court Toronto, Ontario M1B 2K9 www.tevacanada.com Submission Control No: 239062 Date of Preparation: January 11, 2011 Date of Revision: June 3, 2020 _____________________________________________________________________________ _TEVA-QUETIAPINE Page 2 of 56 _ _ _ _ _ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ......................................................... 3 SUMMARY PRODUCT INFORMATION ....................................................................... 3 INDICATIONS AND CLINICAL USE ............................................................................. 3 CONTRAINDICATIONS .................................................................................................. 4 WARNINGS AND PRECAUTIONS ................................................................................. 4 ADVERSE REACTIONS ................................................................................................. 15 DRUG INTERACTIONS ................................................................................................. 28 DOSAGE AND ADMINISTRATION ............................................................................. 30 OVERDOSAGE ............................................................................................................... 32 ACTION AND CLINICAL PHARMACOLOGY ........................................................... 33 STORAGE AND STABILITY ......................................................................................... 35 DOSAGE FORMS, COMPOSITION AND PACKAGING ............................................ 35 PART II: SCIENTIFIC INFORMATION .............................................................................. 37 PHARMACEUTICAL INFORMATION .............. Przeczytaj cały dokument